Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · West Pharmaceutical Services (WST)

West Pharmaceutical raises 2026 sales and EPS guidance after 13.8% Q2 sales rise

Positive Impact 4 of 5 guidance Written later

West Pharmaceutical Services reported second-quarter 2026 net sales of $872.3 million, up 13.8%, and diluted EPS of $2.15, up 18.1%. The company raised its full-year 2026 net sales guidance to $3.345 billion to $3.380 billion and its adjusted-diluted EPS guidance to $8.85 to $9.05, which suggests stronger expected profitability for shareholders.

Key points

  • Q2 2026 net sales of $872.3 million rose 13.8%; organic growth was 12.7%, led by HVP Components at $424.1 million, up 19.4%.
  • Q2 diluted EPS was $2.15, up from $1.82; adjusted-diluted EPS was $2.37, up 28.8%.
  • Full-year 2026 adjusted-diluted EPS guidance rose to $8.85 to $9.05 from $8.40 to $8.75.
  • Q3 2026 adjusted-diluted EPS guidance is $2.14 to $2.24, and Q3 net sales are expected at $820 million to $835 million.

The filing

CompanyWest Pharmaceutical Services (WST)
Form8-K, current report
Filed with the SECJul 23, 2026, 7:14 AM ET
Accession number0000105770-26-000097

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.